Genor Biopharma Holdings Limited (6998.HK)

Name: Genor Biopharma Holdings Limited Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-05-24

Latest Quarter

2026-05-24

Revenue

$32.2M

Net Income

-$54.3M

Operating Margin

-203.8%

Free Cash Flow

-$124M

Debt / Assets

10.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Genor Biopharma Holdings Limited (6998.HK).
Income Statement (Quarterly)	2026-05-24	2025-12-31	2025-06-30	2025-03-31
Revenue	32,244,998	2,414,254,198	32,244,998	16,122,499
Cost of Revenue	0	1,087,409,308	0	0
Gross Profit	32,244,998	1,326,844,889	32,244,998	16,122,499
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	25,113,000	783,960,812	25,113,000	12,556,500
Operating Expenses	97,953,998	864,916,268	97,953,998	48,976,999
Operating Income	-65,709,000	461,928,619	-65,709,000	-32,854,500
Interest Expense	0	151,661,807	0	0
Income Before Tax	-50,007,000	537,159,208	-50,007,000	-25,003,500
Income Tax Expense	4,366,000	91,091,482	4,366,000	2,183,000
Net Income	-54,266,000	445,962,511	-54,266,000	-27,133,000
Per Share
EPS	-0.10	0.34	-0.10	-0.05
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Genor Biopharma Holdings Limited (6998.HK).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	2,423,082,751	206,229,000	0	15,932,000	0
Cost of Revenue	1,081,558,360	1,341,000	0	983,000	0
Gross Profit	1,341,524,390	204,888,000	0	14,949,000	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	573,725,829	71,707,000	125,237,000	217,273,000	305,953,000
Operating Expenses	722,251,687	277,441,000	711,196,000	801,154,000	918,671,000
Operating Income	619,272,706	-72,553,000	-711,196,000	-786,205,000	-859,107,000
Interest Expense	134,947,612	282,000	0	2,856,000	30,928,000
Income Before Tax	483,422,085	-35,132,000	-677,496,000	-732,420,000	-866,306,000
Income Tax Expense	94,492,454	17,842,000	2,280,000	-2,024,000	-932,000
Net Income	388,929,630	-51,283,000	-674,362,000	-730,396,000	-865,224,000
Per Share
EPS	0.23	-0.10	-1.33	-1.45	-1.75
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Genor Biopharma Holdings Limited (6998.HK).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	1,058,790,000	1,165,481,000	1,588,705,000	2,200,641,000
Short Term Investments	0	0	0	0
Net Receivables	0	0	0	0
Inventory	0	5,667,000	47,404,000	49,653,000
Total Current Assets	1,067,293,000	1,241,123,000	1,720,153,000	2,386,578,000
Property Plant Equipment	5,819,000	60,137,000	205,217,000	223,367,000
Goodwill and Intangibles	100,466,000	110,099,000	163,208,000	0
Total Assets	1,289,728,000	1,446,877,000	2,115,091,000	2,862,841,000
Liabilities
Account Payables	82,825,000	141,661,000	132,158,000	129,666,000
Short Term Debt	356,000	3,231,000	6,763,000	37,301,000
Total Current Liabilities	122,086,000	229,525,000	260,395,000	313,188,000
Long Term Debt	555,000	3,924,000	21,823,000	20,107,000
Total Liabilities	138,049,000	256,177,000	309,873,000	369,730,000
Shareholders Equity
Retained Earnings	-6,841,619,000	-6,790,336,000	-6,115,974,000	-5,385,760,000
Total Shareholders Equity	1,151,479,000	1,188,814,000	1,802,478,000	2,490,189,000

Balance sheet annual history for Genor Biopharma Holdings Limited (6998.HK).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	1,058,790,000	1,165,481,000	1,588,705,000	2,200,641,000	2,929,743,000
Short Term Investments	0	0	0	0	0
Net Receivables	0	0	0	0	0
Inventory	0	5,667,000	47,404,000	49,653,000	31,465,000
Total Current Assets	1,067,293,000	1,241,123,000	1,720,153,000	2,386,578,000	3,101,407,000
Property Plant Equipment	5,819,000	60,137,000	205,217,000	223,367,000	229,163,000
Goodwill and Intangibles	100,466,000	110,099,000	163,208,000	0	156,936,000
Total Assets	1,289,728,000	1,446,877,000	2,115,091,000	2,862,841,000	3,573,449,000
Liabilities
Account Payables	82,825,000	141,661,000	132,158,000	129,666,000	91,732,000
Short Term Debt	356,000	3,231,000	6,763,000	37,301,000	15,045,000
Total Current Liabilities	122,086,000	229,525,000	260,395,000	313,188,000	248,730,000
Long Term Debt	555,000	3,924,000	21,823,000	20,107,000	16,014,000
Total Liabilities	138,049,000	256,177,000	309,873,000	369,730,000	336,324,000
Shareholders Equity
Retained Earnings	-6,841,619,000	-6,790,336,000	-6,115,974,000	-5,385,760,000	-4,520,536,000
Total Shareholders Equity	1,151,479,000	1,188,814,000	1,802,478,000	2,490,189,000	3,234,053,000

Cash flow quarterly history for Genor Biopharma Holdings Limited (6998.HK).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-51,283,000	-677,496,000	-732,420,000	-865,224,000
Depreciation & Amortization	0	76,887,000	53,677,000	60,745,000
Stock Based Compensation	11,645,000	60,910,000	48,238,000	123,694,000
Change in Working Capital	-83,541,000	-5,493,000	79,557,000	28,684,000
Operating Cash Flow	-121,979,000	-425,120,000	-577,607,000	-623,741,000
Investing Activities
Capital Expenditure	-1,568,000	-1,034,000	-12,955,000	-71,393,000
Investments	-1,568,000	-1,034,000	-12,955,000	-46,469,000
Investing Cash Flow	8,010,000	5,987,000	-12,940,000	-54,260,000
Financing Activities
Debt Repayment	-1,445,000	-5,936,000	-99,000,000	-34,500,000
Common Stock Issued/Repurchased	0	2,000	-5,134,000	2,722,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-1,557,000	-6,822,000	-57,392,000	17,572,000
Summary
Free Cash Flow	-123,547,000	-426,154,000	-590,562,000	-695,134,000
Net Change in Cash	-106,691,000	-423,224,000	-611,936,000	-729,102,000

Cash flow annual history for Genor Biopharma Holdings Limited (6998.HK).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-51,283,000	-677,496,000	-732,420,000	-865,224,000	-3,027,102,000
Depreciation & Amortization	0	76,887,000	53,677,000	60,745,000	50,485,000
Stock Based Compensation	11,645,000	60,910,000	48,238,000	123,694,000	257,624,000
Change in Working Capital	-83,541,000	-5,493,000	79,557,000	28,684,000	-218,245,000
Operating Cash Flow	-121,979,000	-425,120,000	-577,607,000	-623,741,000	-786,715,000
Investing Activities
Capital Expenditure	-1,568,000	-1,034,000	-12,955,000	-71,393,000	-98,293,000
Investments	-1,568,000	-1,034,000	-12,955,000	-46,469,000	-28,317,000
Investing Cash Flow	8,010,000	5,987,000	-12,940,000	-54,260,000	-98,244,000
Financing Activities
Debt Repayment	-1,445,000	-5,936,000	-99,000,000	-34,500,000	0
Common Stock Issued/Repurchased	0	2,000	-5,134,000	2,722,000	2,735,047,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	-1,557,000	-6,822,000	-57,392,000	17,572,000	3,738,381,000
Summary
Free Cash Flow	-123,547,000	-426,154,000	-590,562,000	-695,134,000	-885,008,000
Net Change in Cash	-106,691,000	-423,224,000	-611,936,000	-729,102,000	2,676,223,000